UNITED STATES, September 03, 2019 (PROACTIVE INVESTORS) – FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) CEO Dr. Raza Bokhari tells Proactive the cannabis company expects to report meaningful medical cannabis sales revenue in 3Q.
Dr. Bokhari says last week, the company reported modest 2Q earnings generated mostly from rental leases. Now, Dr. Bokhari says, because the company has secured a license to sell medicinal cannabis, revenues from this will be realized in its fiscal third quarter.
DISCOVER: FSD Pharma Joins The Stock Day Podcast to Discuss Their Expanding Revenue Potential
About FSD Pharma
FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis. The Company is licensed to cultivate cannabis in approximately 25,000 square feet.
FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019 . FV Pharma intends to cover all aspects of the cannabis industry, including cultivation, legal, processing, manufacturing, extracts and research and development.
